Resources and insights

Albuquerque, New Mexico, USA July 1, 2026 Albuquerque The Magazine profiled EquiSeq in its July 2026 issue. It’s Hereditary Austin Seidel When it comes to sequencing genomes, EquiSeq isn’t horsing around. Founded by scientist Paul Szauter, local startup EquiSeq has spent the last decade helping horse owners better understand life-threatening, inherited diseases through advanced genetic testing. Since launching in 2015, the Albuquerque-based biotech has carved out quite a unique niche for itself in equine genomics – one that could ultimately benefit far more than horses alone. Szauter, Chief Scientific Officer of EquiSeq, earned his Ph.D. in genetics in 1980 before conducting postdoctoral research in molecular biology at MIT. He later worked at the renowned Jackson Laboratory in Bar Harbor, Maine, which he describes as the “center of the universe” for mouse genetics. After relocating to the deserts of New Mexico, he taught at the University of New Mexico and served as Training Director for FlyBase, a cutting-edge bioinformatics database that studies fruit fly genetics to ultimately better understand human disease-causing genes. “I had gotten to know a bunch of entrepreneurs in the community, and I thought, given the uncertainty of federal funding, it would be best to try the private…

Albuquerque, New Mexico, USA June 29, 2026 EquiSeq, a leader in developing genetic tests for horses, is pleased to announce the appointment of Dr. Abigail McElroy, an equestrian and veterinarian currently working on a PhD, to its Board of Directors and Scientific Advisory Board. Dr. McElroy earned her veterinary degree from the Cummings School of Veterinary Medicine at Tufts University in 2017. She then completed a Master’s degree at Michigan State University in 2018, where her research focused on characterizing neurological abnormalities associated with hereditary equine regional dermal asthenia (HERDA). Dr. McElroy is currently a Millennium PhD Candidate at the University of Massachusetts Chan Medical School, where her research focuses on developing a gene therapy for dermatosparaxis Ehlers-Danlos syndrome. In addition to her research, she works part-time in clinical veterinary practice. Abby is also an enthusiastic polo player. “I am thrilled to join both the EquiSeq Board and Scientific Advisory Board,” Dr. McElroy said in a statement. “I bring over 30 years of experience as a horse owner and sport horse competitor to the company, as well experience as a veterinarian with a background in equine genetics. I am excited about the direction that EquiSeq’s research is headed in, and…

April 20, 2026 – Pittsburgh, Pennsylvania The alumni magazine for Carnegie Mellon published an article about Carnegie Mellon alumnus Paul Szauter (B.S. in Biological Sciences, 1976) founder and Chief Scientific Officer of EquiSeq. Read the full article at Carnegie Mellon’s website.

ALBUQUERQUE, NEW MEXICO – April 4, 2026 EquiSeq hosted a webinar on Recurrent Exertional Rhabdomyolysis (RER) on March 30, 2026. Our guest was Kirsten Dimmler, PhD, who recently completed her dissertation on RER at the University of Minnesota under the direction of Dr. Molly McCue. Moderator Madison Sanders and EquiSeq’s Chief Scientific Officer, Paul Szauter, PhD, joined Kirsten for this discussion of what is known, and what is emerging, about this genetically complex disease. In the video, Kirsten reviews current management practices for horses with RER, offering practical advice for owners of affected horses. The video description on the Decoding Horse Health channel on YouTube contains timestamps, allowing horse owners to navigate to specific parts of the video.

ABQ startup hopes to end horse disease with genetic research and testing. View video on KRQE website. Albuquerque, New Mexico – March 11, 2026 NEW MEXICO (KRQE) — Horses are just as much a part of New Mexico’s story as green chile and balloons. One local startup is hoping their research could lead to the end of a debilitating disease in the animal. Paul Szauter openly admits – he’s not a horse person. “When I talk to horse owners… First 30 seconds, they can tell I’m not a horse person, right?” said Szauter. What he does, however, could save future breeds of the animal from suffering a debilitating and painful disease. “Horses are very highly inbred. So they tend to sell horses on the basis of how famous the ancestors were, and if you have this big winning horse, they say, well, let’s have it on both sides of the pedigree, top and bottom,” said Szauter. That practice can lead to genetic mutations within the animals that can cause a condition similar to muscular dystrophy in humans. “That’s called exercise intolerance. And the horse gets older, and it refuses to do the work that it’s been asked to do,” said…

ALBUQUERQUE, NEW MEXICO – January 11, 2026 EquiSeq was profiled in the Business section of the Albuquerque Journal on January 11, 2026. The article, by writer Hannah Garcia, described the company’s origins and the road ahead, based on interviews with Paul Szauter, Chief Scientific Officer; Madison Sanders, an equestrian who is a member of EquiSeq’s Board of Directors; and Jeremy Edwards, a scientist at the University of New Mexico. Coverage was prompted by the issuance of a second U.S. patent for DNA testing of horses to detect the predisposition to muscle disease. Please see the full article in the Albuquerque Journal.

ALBUQUERQUE, New Mexico – December 16, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 16/088,247, “Method of Detecting Inherited Equine Myopathy.” The patent includes claims covering specific genetic mutations that predispose to muscle disease in horses, allowing the design of a rational breeding program to reduce the incidence of equine muscle disease. The patent, and EquiSeq’s other patent, U.S. Patent Number 12,398,426, “Methods of Detecting Inherited Myopathies in Horses,” describe the use of DNA testing to identify damaging genetic variants in six different horse genes. The patented technology has been in commercial use since 2017, with over 15,000 horses tested. The test is sold directly to consumers, including horse owners, breeders, and veterinarians. The technology has been licensed by Generatio GmbH, a company in Germany that provides equine genetic testing for Europe. DNA testing is a well-established technology that works reliably on all DNA, regardless of the source. In the United States, EquiSeq uses allele-specific PCR, a rapid test that returns results quickly enough for a pre-purchase exam. In Germany, Generatio uses an Illumina BeadArray, a comprehensive test for tens of thousands of variants….

ALBUQUERQUE, NEW MEXICO – November 13, 2025 EquiSeq held its first Decoding Horse Health webinar on Zoom on November 11, 2025. Madison Sanders (Elite Equine Marketplace and EquiSeq) interviewed Paul Szauter, PhD (EquiSeq’s Chief Scientific Officer) and Stephanie Carter, FNTP (Indigo Ancestral Health). The webinar focused on inherited muscle disease in horses. Dr. Szauter discussed the founding of the company, the research behind its patented tests, and methods used to evaluate scientific work, including review by patent examiners and the peer-reviewed scientific literature. Stephanie Carter, who recently published Managing Muscle Mayhem, discussed management of affected horses through diet and other means. She reported that some affected horses are able to return to work of some kind with proper management. People attending the webinar were able to ask questions. The panelists expressed hope that this webinar will facilitate communication between horse owners and their veterinarians on this emerging area of horse health. A video of the webinar is posted on the Decoding Horse Health channel on YouTube.

ALBUQUERQUE, NEW MEXICO – October 14, 2025 The October 2025 issue of Equine Business Magazine published an article on EquiSeq, describing its DNA test as changing the landscape in managing horse health. Madison Ruddy Sanders, founder of Elete Equine Marketplace and a member of EquiSeq’s Board of Directors, wrote the article, based on conversations with Paul Szauter, EquiSeq’s Chief Scientific Officer; Stephanie Carter, an equine nutritionist; and horse owners Wendee Walker and Charlene Shingleton. EquiSeq’s patented DNA tests identify horses at risk for a muscle disease before they develop symptoms. Unlike muscle biopsy, EquiSeq’s DNA test is noninvasive, only requiring a hair sample. The article is one of the outcomes of EquiSeq’s recent outreach to horse owners. Madison Sanders and Paul Szauter have interviewed horse owners via Zoom, offering the opportunity for horse owners to write guest blog posts for EquiSeq’s website. They are currently planning public webinars to address horse muscle disease.

ALBUQUERQUE, New Mexico – September 2, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 12,398,426, “Methods of Detecting Inherited Myopathies in Horses.” The patent includes claims covering specific genetic mutations that predispose to muscle disease in horses, allowing the design of a rational breeding program to reduce the incidence of equine muscle disease. The patent, and EquiSeq’s other patent, U.S. Patent Number 16/088,247, “Method of Detecting Inherited Equine Myopathy,” describe the use of DNA testing to identify damaging genetic variants in six different horse genes. The patented technology has been in commercial use since 2017, with thousands of horses tested. The test is sold directly to consumers, including horse owners, breeders, and veterinarians. The technology has been licensed by Generatio GmbH, a company in Germany that provides equine genetic testing for Europe. DNA testing is a well-established technology that works reliably on all DNA, regardless of the source. In the United States, EquiSeq uses allele-specific PCR, a rapid test that returns results quickly enough for a pre-purchase exam. In Germany, Generatio uses an Illumina BeadArray, a comprehensive test for tens of thousands of variants….